低分子肝素钠与低分子肝素钙治疗儿童过敏性紫癜的临床疗效比较  

Comparison of clinical efficacy between low molecular weight heparin sodium and low molecular weight heparin calcium in treatment of children with Henoch-Schonlein purpura

作　　者：刘青青 陈玲 金欣 Liu Qing-qing;Chen Ling;Jin Xin(The Second Department of Pediatrics,3201 Hospital,Hanzhong 723000,China)

机构地区：[1]三二〇一医院儿二科,汉中723000

出　　处：《中国药物应用与监测》2025年第2期280-283,共4页Chinese Journal of Drug Application and Monitoring

摘　　要：目的比较低分子肝素钠与低分子肝素钙治疗过敏性紫癜(HSP)患儿的临床疗效。方法选择2022年3月至2024年3月于三二〇一医院儿科治疗的HSP患儿120例,采用随机数字表法将患者分为低分子肝素钠治疗组(NA组)和低分子肝素钙治疗组(CA组),每组各60例。NA组治疗方案:患者接受常规治疗+皮下注射低分子肝素钠;CA组治疗方案:患者接受常规治疗+皮下注射低分子肝素钙。比较两组疗效、症状消退时间、凝血功能、β2微球蛋白、尿白蛋白水平以及不良反应发生情况。结果CA组治疗总有效率(96.67%)和NA组总有效率(93.33%)差异无统计学意义(χ^(2)=0.175,P>0.05)。治疗后,CA组过敏性紫癜患儿皮肤紫癜和胃肠道反应的消退时间短于NA组[分别是(1.02±0.45)d vs(2.46±1.33)d、(2.93±0.56)d vs(4.25±0.98)d](t=7.944、9.059,均P<0.05);治疗后,两组凝血酶原时间、凝血活酶时间和血小板计数[分别是(17.98±4.02)s vs(17.02±3.37)s、(41.67±3.54)s vs(40.56±3.01)s、(190.98±51.76)×10^(9)·L^(-1) vs(192.87±51.45)×10^(9)·L^(-1)],差异无统计学意义(t=1.418、1.850、-0.201,均P>0.05);治疗后,NA组β2微球蛋白、尿白蛋白水平均较CA组高[分别是(12.98±1.89)μg·mL^(-1) vs(10.25±1.64)μg·mL^(-1)、(0.41±0.08)μg·mL^(-1) vs(0.35±0.07)μg·mL^(-1)],差异无统计学意义(t=8.451、4.372,均P<0.05)。治疗后,NA组和CA组不良反应发生率(3.33%vs 1.67%),差异无统计学意义(χ^(2)=0.000,P>0.05)。结论在治疗过敏性紫癜患儿时,应用低分子肝素钙治疗较低分子肝素钠治疗皮肤紫癜和胃肠道反应的消退时间短,肾功能改善效果较好。Objective To compare the clinical efficacy of low molecular weight heparin sodium and low molecular weight heparin calcium in the treatment of children with Henoch-Schonlein purpura(HSP).Methods A total of 120 children patients with HSP treated in 3201 Hospital from March 2022 to March 2024 were selected as the research subjects and divided into low-molecular-weight heparin sodium treatment group(NA group)and low-molecular-weight heparin calcium treatment group(CA group)by using the random number table method,with 60 in each group.The patients in the NA group received routine treatment+subcutaneous injection of low-molecular-weight heparin sodium and those in the CA group received routine treatment+subcutaneous injection of low-molecular-weight heparin calcium.The curative effects,symptom regression time,coagulation function,β2-microglobulin,urine albumin level and occurrence of adverse reactions were compared between the two groups.Results There was no statistically significant difference in the total effective rate of treatment between the CA group(96.67%)and the NA group(93.33%)(χ^(2)=0.175,P>0.05).After treatment,the fading time of skin purpura and gastrointestinal reactions in children with allergic purpura in CA group was shorter than that in the NA group((1.02±0.45)d vs(2.46±1.33)d,(2.93±0.56)d vs(4.25±0.98)d)(t=7.944,9.059,both P<0.05).There was no significant difference in prothrombin time,thromboplastin time and platelet count between the two groups((17.98±4.02)s vs(17.02±3.37)s,(41.67±3.54)s vs(40.56±3.01)s,(190.98±51.76)×109·L^(-1) vs(192.87±51.45)×109·L^(-1))(t=1.418,1.850,-0.201,all P>0.05).The levels ofβ2-microglobulin and urinary albumin in the NA group were both higher than those in the CA group((12.98±1.89)μg·mL^(-1) vs(10.25±1.64)μg·mL^(-1),(0.41±0.08)μg·mL^(-1) vs(0.35±0.07)μg·mL^(-1)),showing no significant difference(t=8.451,4.372,both P<0.05).The incidence of adverse reactions was not significantly different between the NA group and CA group(3.33%vs 1.67%)(χ^(2

关 键 词：低分子肝素钠 低分子肝素钙 过敏性紫癜 儿童 疗效 

分 类 号：R725.5[医药卫生—儿科]